Our vision is to pioneer a paradigm shift in mental health that empowers the healing process.
Updates:

Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Helus Pharma Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
Led By Science
Advancing Mental Health with Novel Serotonergic Agonists (NSAs)


HELUS Pharma’s mission is to provide treatments designed to foster durable improvements in mental health to help minds heal. We strategically innovate novel serotonergic agonists (NSA)1 through rigorous patient-centered research and clinical excellence.
1Novel serotonergic agonist: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.

NEXT GENERATION THERAPIES
We are pioneering next-generation therapies that pair novel serotonergic agonists with precision drug delivery systems through our proprietary deuteration technology.

OUR TECHNOLOGY
Our technology creates consistent delivery, commercially scalable, patent protected treatments designed to transform mental health care.
Helus
by the
numbers:
3
Active drug
programs.
250+
Patent
applications
pending.
100+
Granted
patents.
Led by Experts in
Mental Health Innovation
Our team brings deep pharmaceutical development and regulatory expertise to our mental health therapeutic programs. Our scientific leadership includes experience in neuropsychiatry, oversight of 60+ IND programs, and a strong track record of developing multiple commercially available pharmaceutical therapies including over 10 blockbuster drugs.

Eric So
Co-Founder, Executive Chairman & Interim Chief Executive Officer

Amir Inamdar MBBS, DNB (Psych), MFPM
Chief Medical Officer

Lori Challenger
Chief Compliance, Ethics & Administrative Officer
